<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189319</url>
  </required_header>
  <id_info>
    <org_study_id>1478-FLEC</org_study_id>
    <nct_id>NCT00189319</nct_id>
  </id_info>
  <brief_title>To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>Impact of Oral Controlled Release Flecainide Acetate Capsules on Health-Related QoL in Patients With Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the management of paroxysmal atrial fibrillation
      with controlled release flecainide on patient's quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect of Flecainide CR on patient-perceived health-related QoL (Quality of Life).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>assessment of treatment success based on an efficacy/safety composite criterion;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of the relationship between QoL changes and outcomes related to safety and efficacy;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of cardiac safety of Flecainide CR through clinical examination, cardiac adverse events,12-lead paper ECG, and cardiac ultrasonography;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of the non-cardiac safety of Flecainide CR through questioning, non-cardiac adverse events and clinical examination;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of the course of the disease by the time to the first recurrence of a PAF episode and the subjective symptomatology (duration and severity of PAF episodes).</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flecainide controlled release</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In sinus rhythm at treatment initiation

          -  Experienced symptomatic AF episodes

          -  Left ventricular ejection fraction of at least 40%

          -  Females of child bearing potential must be using reliable method of contraception

        Exclusion Criteria:

          -  Intolerance and/or failure of previous therapy with flecainide immediate release

          -  Currently receiving &gt;200mg/day flecainide immediate release

          -  Severe symptoms during episodes of arrhythmia

          -  History of other cardiac conditions/abnormalities

          -  Heart surgery within the last 2 months

          -  Renal failure

          -  Pregnant or lactating females

          -  Significant extra cardiac or systemic disease

          -  Abnormal electrolyte levels

          -  Receiving defined cardiac and/or other treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salem Kacet</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Cardiologique, CHR de Lille, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Cardiologique, Service de Cardiologique CHR de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>February 20, 2007</last_update_submitted>
  <last_update_submitted_qc>February 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2007</last_update_posted>
  <keyword>Tambocor</keyword>
  <keyword>Paroxysmal Atrial Fibrillation</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

